NeoGenomics [NEO] vs Veracyte [VCYT] Detailed Stock Comparison
NeoGenomics
NASDAQ
Loading...
Veracyte
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: NeoGenomics wins in 6 metrics, Veracyte wins in 12 metrics, with 0 ties. Veracyte appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | NeoGenomics | Veracyte | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -8.22 | 57.07 | NeoGenomics |
| Price-to-Book Ratio | 0.93 | 1.57 | NeoGenomics |
| Debt-to-Equity Ratio | 68.09 | 4.23 | Veracyte |
| PEG Ratio | 32.30 | 59.93 | NeoGenomics |
| EV/EBITDA | 1,640.89 | 26.97 | Veracyte |
| Profit Margin (TTM) | -11.54% | 7.13% | Veracyte |
| Operating Margin (TTM) | -16.56% | 7.03% | Veracyte |
| EBITDA Margin (TTM) | N/A | 7.03% | N/A |
| Return on Equity | -8.57% | 2.86% | Veracyte |
| Return on Assets (TTM) | -2.75% | 1.94% | Veracyte |
| Free Cash Flow (TTM) | $-34.04M | $63.81M | Veracyte |
| 1-Year Return | -70.30% | 10.97% | Veracyte |
| Price-to-Sales Ratio (TTM) | 1.24 | 4.05 | NeoGenomics |
| Enterprise Value | $1.08B | $1.68B | Veracyte |
| EV/Revenue Ratio | 1.60 | 3.62 | NeoGenomics |
| Gross Profit Margin (TTM) | 43.59% | 69.46% | Veracyte |
| Revenue per Share (TTM) | $5 | $6 | Veracyte |
| Earnings per Share (Diluted) | $-0.61 | $0.42 | Veracyte |
| Beta (Stock Volatility) | 1.62 | 2.07 | NeoGenomics |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
NeoGenomics vs Veracyte Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| NeoGenomics | -2.86% | -22.84% | -30.23% | -20.31% | -65.54% | -69.07% |
| Veracyte | -2.04% | -0.99% | -11.32% | -21.41% | -48.05% | -40.73% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| NeoGenomics | -70.30% | -50.05% | -87.15% | -11.46% | 376.64% | 1,175.00% |
| Veracyte | 10.97% | -14.09% | -25.90% | 138.51% | 94.88% | 94.88% |
Performance & Financial Health Analysis: NeoGenomics vs Veracyte
| Metric | NEO | VCYT |
|---|---|---|
| Market Information | ||
| Market Cap | $831.37M | $1.88B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,715,660 | 3,085,135 |
| 90 Day Avg. Volume | 1,882,183 | 1,674,092 |
| Last Close | $5.10 | $23.97 |
| 52 Week Range | $4.81 - $19.11 | $19.73 - $47.32 |
| % from 52W High | -73.31% | -49.34% |
| All-Time High | $61.57 (Feb 15, 2021) | $86.03 (Feb 08, 2021) |
| % from All-Time High | -91.72% | -72.14% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.18% |
| Quarterly Earnings Growth | 0.08% | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | -0.12% | 0.07% |
| Operating Margin (TTM) | -0.17% | 0.07% |
| Return on Equity (TTM) | -0.09% | 0.03% |
| Debt to Equity (MRQ) | 68.09 | 4.23 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.92 | $15.26 |
| Cash per Share (MRQ) | $2.78 | $3.67 |
| Operating Cash Flow (TTM) | $7.61M | $89.42M |
| Levered Free Cash Flow (TTM) | $-759,125 | $76.93M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: NeoGenomics vs Veracyte
| Metric | NEO | VCYT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -8.22 | 57.07 |
| Forward P/E | 32.30 | 59.93 |
| PEG Ratio | 32.30 | 59.93 |
| Price to Sales (TTM) | 1.24 | 4.05 |
| Price to Book (MRQ) | 0.93 | 1.57 |
| Market Capitalization | ||
| Market Capitalization | $831.37M | $1.88B |
| Enterprise Value | $1.08B | $1.68B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.60 | 3.62 |
| Enterprise to EBITDA | 1,640.89 | 26.97 |
| Risk & Other Metrics | ||
| Beta | 1.62 | 2.07 |
| Book Value per Share (MRQ) | $6.92 | $15.26 |
Financial Statements Comparison: NeoGenomics vs Veracyte
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NEO | VCYT |
|---|---|---|
| Revenue/Sales | $168.04M | $114.47M |
| Cost of Goods Sold | $94.79M | $34.97M |
| Gross Profit | $73.25M | $79.51M |
| Research & Development | $10.18M | $17.72M |
| Operating Income (EBIT) | $-27.83M | $1.16M |
| EBITDA | $-6.31M | $3.03M |
| Pre-Tax Income | $-25.66M | $7.43M |
| Income Tax | $266,000 | $381,000 |
| Net Income (Profit) | $-25.92M | $7.05M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NEO | VCYT |
|---|---|---|
| Cash & Equivalents | $346.19M | $186.12M |
| Total Current Assets | $573.93M | $383.15M |
| Total Current Liabilities | $279.70M | $75.13M |
| Long-Term Debt | $400.58M | $43.09M |
| Total Shareholders Equity | $888.27M | $1.19B |
| Retained Earnings | $-351.70M | $-436.94M |
| Property, Plant & Equipment | $366.10M | $70.15M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NEO | VCYT |
|---|---|---|
| Operating Cash Flow | $735,000 | $18.76M |
| Capital Expenditures | $-4.50M | $-1.82M |
| Free Cash Flow | $-29.83M | $3.54M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NEO | VCYT |
|---|---|---|
| Shares Short | 4.27M | 6.11M |
| Short Ratio | 2.18 | 6.38 |
| Short % of Float | 0.05% | 0.09% |
| Average Daily Volume (10 Day) | 1,715,660 | 3,085,135 |
| Average Daily Volume (90 Day) | 1,882,183 | 1,674,092 |
| Shares Outstanding | 128.15M | 77.77M |
| Float Shares | 127.06M | 77.87M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 0.98% | 1.08% |
Dividend Analysis & Yield Comparison: NeoGenomics vs Veracyte
| Metric | NEO | VCYT |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |